<?xml version="1.0" encoding="UTF-8"?>
<p>This article explains how the renin-angiotensin system (RAS) interacts with the severe acute respiratory syndrome coronavirus (SARS-CoV) and also with the novel coronavirus, SARS-CoV-2, which causes infection and subsequent acute lung and probably heart injury [COVID-19 (
 <xref rid="B1" ref-type="bibr">1</xref>–
 <xref rid="B3" ref-type="bibr">3</xref>)]. As well as identifying potential therapeutic strategies for treating acute lung injury and myocarditis in COVID-19 [see also (
 <xref rid="B4" ref-type="bibr">4</xref>–
 <xref rid="B6" ref-type="bibr">6</xref>)], this article provides a background to the management of patients with essential hypertension in accordance with recommendations made in the joint statement issued by the Heart Failure Society of America, the American College of Cardiology and the American Heart Association (
 <xref rid="B7" ref-type="bibr">7</xref>) that patients who are using drugs that block the RAS should continue to use them during this pandemic. It also describes why the use of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) is associated with less severe COVID-19 infections (
 <xref rid="B8" ref-type="bibr">8</xref>, 
 <xref rid="B9" ref-type="bibr">9</xref>).
</p>
